Covance forms new unit focused on biologic drug development

Eisai and UCL ready clinical study for antibody aimed at Alzheimer’s
Credit: Pressmaster

LabCorp’s Covance Drug Development business has formed a global immunology and immunotoxicology (I&I) unit dedicated to the specific needs of biologic drug development.

This team brings together Covance’s operational aptitude in flow cytometry, immunoassays and cell-based assays with its scientific expertise in immunotoxicology study design, direction and operation to provide a more comprehensive offering for large-molecule drugs.

CEO John Ratliff said: “Biologics make up more than one-third of biopharma’s pipeline. Integrating our scientific and operational know-how into a seamless group allows us to deliver even richer scientific insights and faster cycle times for clients’ biologic programs, which helps our clients bring cutting-edge new drugs to patients faster.”

The new I&I unit’s comprehensive offering includes a seamless bridge to bioanalysis for use in regulatory submissions and to Covance Phase I clinical research units for first-in-human and first-in-patient studies.

As studies progress, the I&I team can complete its unique set of solutions by drawing on additional expertise from Covance’s clinical development and commercialisation, translational biomarker, immuno-oncology and central laboratory teams, as well as LabCorp’s specialist scientific and technical capabilities.

The formation of Covance’s I&I unit illustrates LabCorp’s continued focus on biologics, which extends through LabCorp Diagnostics’ expanding suite of biologic therapeutic drug monitoring tests.

Steve Street, senior vice president of Covance Early Development, said: “In addition to study design, development and direction, the global innovation team within our I&I unit will focus on new assay development and validation, keeping Covance at the forefront of biologic research and development.”